These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10450523)

  • 21. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.
    Coutinho A; Caramalho I; Seixas E; Demengeot J
    Curr Top Microbiol Immunol; 2005; 293():43-71. PubMed ID: 15981475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different modes of pathogenesis in T-cell-dependent autoimmunity: clues from two TCR transgenic systems.
    Ji H; Korganow AS; Mangialaio S; Höglund P; André I; Lühder F; Gonzalez A; Poirot L; Benoist C; Mathis D
    Immunol Rev; 1999 Jun; 169():139-46. PubMed ID: 10450514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Viral antigen induced autoimmunity: an animal model for diabetes mellitus type I].
    Hengartner H
    Verh Dtsch Ges Pathol; 1994; 78():177-9. PubMed ID: 7533982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TLR7 stimulation augments T effector-mediated rejection of skin expressing neo-self antigen in keratinocytes.
    Zhong J; Hadis U; De Kluyver R; Leggatt GR; Fernando GJ; Frazer IH
    Eur J Immunol; 2008 Jan; 38(1):73-81. PubMed ID: 18157820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
    Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
    Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4-positive and B lymphocytes in transplantation immunity. I. Promotion of tumor allograft rejection through elimination of CD4-positive lymphocytes.
    Koeppen HK; Singh S; Stauss HJ; Park BH; Rowley DA; Schreiber H
    Transplantation; 1993 Jun; 55(6):1349-55. PubMed ID: 8100089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transient T and B cell activation after neonatal induction of tolerance to MHC class II or Mls alloantigens.
    Schurmans S; Brighouse G; Kramer G; Wen L; Izui S; Merino J; Lambert PH
    J Immunol; 1991 Apr; 146(7):2152-60. PubMed ID: 1672344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hepatocellular carcinoma with the cellular tumor vaccines generated by in vitro modification of tumor cells with non gene transfer approaches.
    Wu S; Ma J; Che X; Liu Y; Wang H; Zhao J; Shen F; Xie T; Trojan J; Wu M; Guo Y
    Adv Exp Med Biol; 1998; 451():283-93. PubMed ID: 10026886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Positive and negative selection of T cells in T-cell receptor transgenic mice expressing a bcl-2 transgene.
    Strasser A; Harris AW; von Boehmer H; Cory S
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1376-80. PubMed ID: 8108419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity.
    Morgan DJ; Kreuwel HT; Fleck S; Levitsky HI; Pardoll DM; Sherman LA
    J Immunol; 1998 Jan; 160(2):643-51. PubMed ID: 9551898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On the role of unmutated antigens in tumor rejection in mice with unperturbed T-cell repertoires.
    Sarma S; Bai XF; Liu JQ; May KF; Zheng P; Liu Y
    Cancer Res; 2003 Sep; 63(18):6051-5. PubMed ID: 14522934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Death by neglect as a deletional mechanism of peripheral tolerance.
    Bertolino P; Trescol-Biémont MC; Thomas J; Fazekas de St Groth B; Pihlgren M; Marvel J; Rabourdin-Combe C
    Int Immunol; 1999 Aug; 11(8):1225-38. PubMed ID: 10421780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
    Eck SC; Turka LA
    Cancer Res; 2001 Apr; 61(7):3077-83. PubMed ID: 11306490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy.
    Speiser DE; Miranda R; Zakarian A; Bachmann MF; McKall-Faienza K; Odermatt B; Hanahan D; Zinkernagel RM; Ohashi PS
    J Exp Med; 1997 Aug; 186(5):645-53. PubMed ID: 9271580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purified donor T cells alone activate transplantation immunity to the male antigen but induce tolerance in combination with Mac-1+ donor cells.
    Sheng B; McCormack WT; Smith RT
    Transplantation; 1999 Oct; 68(7):1024-9. PubMed ID: 10532545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
    Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
    J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Sreedharan S; Mohanty K; Bhattacharya-Chatterjee M
    Cancer Res; 2004 Jul; 64(14):4995-5003. PubMed ID: 15256474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.